Latest Breaking News On - Nuclear receptors - Page 1 : vimarsana.com

UH Researcher on Team Developing Sense-and-Respond Cancer Implant Technology

Federally funded research project could slash US cancer deaths by half. Dr. Weiyi Peng, assistant professor of biology and biochemistry, is co-principal investigator and one of three group leaders of the project.

Rice universityUnited statesNorthwestern universityUniversity of houstonWeiyi pengOmid veisehChunyu xuCarnegie mellon universityNuclear receptorsVenture groupUniversity of texas md anderson cancer centerUh college of natural sciencesUniversity of houston college natural sciencesResearch projects agency for healthBrandon martin rice universityBroad agency announcement

Making immunotherapy safer

Researchers at the University of Houston are working to make T-cell immunotherapy safer, developing a tool called CrossDome, which uses a combination of genetic and biochemical information to predict if T-cell immunotherapies might mistakenly attack healthy cells.

Andref fonsecaDinler antunesNuclear receptorsUniversity of houstonComputational biology

CrossDome tool helps predict the potential risks of T-cell immunotherapy

Researchers at the University of Houston are working to make T-cell immunotherapy safer, developing a tool called CrossDome, which uses a combination of genetic and biochemical information to predict if T-cell immunotherapies might mistakenly attack healthy cells.

Megan craigDinler antunesAndref fonsecaNuclear receptorsUniversity of houstonComputational biologyAssistant professorCell signalingT cell

New tool predicts if immunotherapy will mistakenly attack healthy cells

New tool predicts if immunotherapy will mistakenly attack healthy cells
medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.

Dinler antunesAndref fonsecaUniversity of houstonNuclear receptorsComputational biology

Study provides a possible treatment option for prostate cancer resistant to hormone therapy

Prostate cancer is the most-commonly diagnosed malignancy and the second leading cause of cancer death among men in the United States.

United statesChong shenRamesh singhMegan craigLance lumahanSteven nguyenUniversity of houstonBaylor college of medicineDepartment of biologyDepartment of molecularNuclear receptorsCellular biologyBaylor collegeCell signaling